Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2608204 Monotherapy or Combination in Type 2 Diabetes
NCT01408095Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of globalagliatin in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Planned start Sep 2011; status: withdrawn.
02
Drugs
globalagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01408095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408095.